Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Mabwell (Shanghai) Bioscience Co., Ltd. clinical trials
The registry lists 61 studies whose lead sponsor is Mabwell (Shanghai) Bioscience Co., Ltd. or one of 1 company grouped under it. 25 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Mabwell (Shanghai) Bioscience Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Mabwell (Shanghai) Bioscience Co., Ltd..
- Mabwell (Shanghai) Bioscience Co., Ltd.53 studiesSame company
Something wrong?
- Jiangsu T-Mab Biopharma Co.,Ltd8 studies →Acquired — became part of Mabwell (Shanghai) Bioscience Co., Ltd., Sep 5, 2017 · source ↗
Something wrong?
Focus areas
Conditions Mabwell (Shanghai) Bioscience Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 61. Browse all 61 →
- A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCsRecruitingNCT06908928Phase 1
- A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior ChemoimmunotherapyNot yet recruitingNCT07831863Phase 3
- First-in-human Study of 7MW4911 in GI CancerRecruitingNCT07216560Phase 1/2
- A Phase II Study of 9MW3811 in Patients With Pathological ScarRecruitingNCT07576608Phase 2
- A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07556848Phase 3
- A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsRecruitingNCT07466160Phase 1/2
- 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial CancerRecruitingNCT07314723Phase 2
- First-in-human Study of 7MW4911 in Patients With Advanced Solid TumorsRecruitingNCT07265622Phase 1/2
- A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)RecruitingNCT07292714Phase 2
- A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraRecruitingNCT06752746Phase 1
- A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid TumorsNot yet recruitingNCT06947226Phase 1/2
- 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological TumorsNot yet recruitingNCT06926998Phase 1/2
- A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerRecruitingNCT06196736Phase 3
- 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06823427Phase 2
- A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaRecruitingNCT06772766Phase 1
- A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerRecruitingNCT06492005Phase 2
- A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical CancerRecruitingNCT06692166Phase 3
- 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerRecruitingNCT06079112Phase 1/2
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerRecruitingNCT06592326Phase 3
- A Clinical Study of 9MW2821 in Advanced Malignant Solid TumorsRecruitingNCT05773937Phase 1
- A Phase 1/2 Study of 7MW3711 in Advanced Solid TumorsRecruitingNCT06008366Phase 1/2
- A Study of 7MW3711 in Subjects With Advanced Solid TumorsRecruitingNCT06008379Phase 1/2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy SubjectsRecruitingNCT05912049Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid TumorsNot yet recruitingNCT05911984Phase 1
- A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid TumorsRecruitingNCT05216965Phase 1/2
- A Phase I Study of 9MW4113 Injection Versus Dupixent®Active, not recruitingNCT07791342Phase 1
- A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With OsteoporosisCompletedNCT06804590Phase 3
- An Evaluation of 9MW1911 Injection in Healthy SubjectsCompletedNCT05803902Phase 1
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy SubjectsCompletedNCT05740475Phase 1
- Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).Active, not recruitingNCT06175351Phase 1/2
- Single Ascending Dose Study of 9MW3011 in Chinese Healthy SubjectCompletedNCT06389942Phase 1
- Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid TumorsActive, not recruitingNCT05990452Phase 1/2
- A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid TumorsSuspendedNCT05416749Phase 1/2
- A Clinical Study in Healthy Subjects to Evaluate 9MW1911 InjectionCompletedNCT05170243Phase 1
- Efficacy and Safety of MW031 in PMO SubjectsCompletedNCT05215977Phase 3
- A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSStatus unknownNCT05448599Phase 1/2
- Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid TumorsCompletedNCT04812509Phase 3
- Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSFCompletedNCT04554056Phase 2/3
- 6MW3511 in Patients With Advanced Solid TumorStatus unknownNCT05524194Phase 1/2
- A Clinical Study of 6MW3211 in Patients With Renal CancerStatus unknownNCT05440045Phase 2
- A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory LymphomaStatus unknownNCT05446688Phase 2
- A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung CancerStatus unknownNCT05431569Phase 2
- A Clinical Study in Health Subjects to Evaluate 9MW1411 InjectionCompletedNCT04784312Phase 1
- A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant NeoplasmStatus unknownNCT05048160Phase 1/2
- A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure InfectionsStatus unknownNCT05339802Phase 2
- Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular EdemaStatus unknownNCT05324774Phase 3
- Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular EdemaCompletedNCT05324592Phase 1
- A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMDStatus unknownNCT05297292Phase 2/3
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy AdultsCompletedNCT04798326Phase 1
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy AdultsCompletedNCT04798313Phase 1